



(12) **CORRECTED EUROPEAN PATENT SPECIFICATION**

Note: Bibliography reflects the latest situation

- (15) Correction information:  
**Corrected version no 1 (W1 B1)**  
**Corrections, see page(s) 7**
- (48) Corrigendum issued on:  
**28.09.2005 Bulletin 2005/39**
- (45) Date of publication and mention  
of the grant of the patent:  
**04.05.2005 Bulletin 2005/18**
- (21) Application number: **01910860.4**
- (22) Date of filing: **16.02.2001**
- (51) Int Cl.7: **A61K 31/20, A23K 1/16,**  
**A23K 1/18, A61P 19/00**
- (86) International application number:  
**PCT/US2001/005094**
- (87) International publication number:  
**WO 2001/060356 (23.08.2001 Gazette 2001/34)**

(54) **METHOD FOR IMPROVING BONE MODELING AND CHONDROCYTE FUNCTIONING IN GROWING CANINES**

VERFAHREN ZUR VERBESSERTER KNOCHENFORMUNG UND CHONDROZYTENBETRIEB IN WACHSENDEN HUNDEN

PROCEDE DESTINE A AMELIORER LA MODELISATION OSSEUSE ET LE FONCTIONNEMENT DU CHONDROCYTE CHEZ LES CHIENS EN PERIODE DE CROISSANCE

- |  |  |
|--|--|
| <p>(84) Designated Contracting States:<br/><b>AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU</b><br/><b>MC NL PT SE TR</b></p> <p>(30) Priority: <b>17.02.2000 US 183294 P</b></p> <p>(43) Date of publication of application:<br/><b>13.11.2002 Bulletin 2002/46</b></p> <p>(73) Proprietor: <b>THE IAMS COMPANY</b><br/><b>Ohio 45414 (US)</b></p> <p>(72) Inventors:<br/> <ul style="list-style-type: none"> <li>• <b>WATKINS, Bruce, A.</b><br/><b>West Lafayette, IN 47906 (US)</b></li> <li>• <b>LEPINE, Allan, J.</b><br/><b>Dayton, OH 45414 (US)</b></li> <li>• <b>HAYEK, Michael, G.</b><br/><b>Dayton, OH 45415 (US)</b></li> <li>• <b>REINHART, Gregory, A.</b><br/><b>Dayton, OH 45414 (US)</b></li> </ul> </p> | <p>(74) Representative: <b>Clemo, Nicholas Graham et al</b><br/><b>Procter &amp; Gamble Technical Centres Limited</b><br/><b>Patent Department</b><br/><b>Rusham Park,</b><br/><b>Whitehall Lane</b><br/><b>Egham, Surrey TW20 9NW (GB)</b></p> <p>(56) References cited:<br/><b>EP-A- 0 585 026</b>                      <b>US-A- 5 069 903</b></p> <ul style="list-style-type: none"> <li>• <b>ROGERS, L. L., WATKINS, B. A., TUREK, J. J., SCHOLEIN, I. A., LEPINE, A. J., REINHART, G. A., AND LI, Y.:</b> "Dietary n-3 and n-6 fatty acids effects on canine bone and ligament composition" <b>FASEB JOURNAL.</b>, vol. 14, no. 4, 15 March 2000 (2000-03-15), page a252 <b>XP002172303 FED. OF AMERICAN SOC. FOR EXPERIMENTAL BIOLOGY, BETHESDA, MD., US ISSN: 0892-6638</b></li> <li>• <b>SIMOPOULOS, A. P.:</b> "The return of omega-3 fatty acids into the food supply. 1. Land based animal food products and their health effects" 1998, <b>S KARGER, BASEL XP002172304 Part 1:omega-3 Fatty acids and Health. "Regulatory effects of polyunsaturates on bone modeling and cartilage function", p. 38-51</b></li> </ul> |
|--|--|

Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).

- **SIMOPOULOS, A. P. (ED.): "The return of omega-3 fatty acids into the food supply. 1. Land based animal food products and their health effects" 1998, S KARGER, BASEL XP002172305 Part 3: Companion Animal Nutrition. "Utilization of omega-3 fatty acids in companion animal nutrition", p. 176-185**
- **DATABASE WPI Section Ch, Week 199243 Derwent Publications Ltd., London, GB; Class B05, AN 1992-352741 XP002172306 & JP 04 253908 A (NIPPON OILS AND FATS CO LTD), 9 September 1992 (1992-09-09)**

## Description

**[0001]** The present invention relates to the use of a pet food composition comprising appropriate amounts and ratios of n-6/n-3 fatty acids to enhance bone modeling and chondrocyte functioning in growing canines.

**[0002]** It is known from Canadian Patent No. 2,145,716 that dietary n-6 and n-3 fatty acids (also known as omega-6 and omega-3 fatty acids) and the ratio in which they are present in the canine diet has an effect on the skin and coat health of the animal. Studies have demonstrated that the incorporation of optimal proportions of n-6 and n-3 fatty acids into the diet has a beneficial effect on canines suffering from certain inflammatory skin conditions.

**[0003]** Hayek and Reinhart "Utilization of  $\omega$ -3 Fatty Acids in Companion Animal Nutrition" (1998) in "The Return of  $\omega$ -3 Fatty Acids into the Food Supply I" (Simopoulos, AP ed.), World Rev Nutr Diet, Basel, Karger, vol. 8, pp176-185 discloses companion animal compositions comprising  $\omega$ -6 and  $\omega$ -3 fatty acids. Watkins "Regulatory Effects of Polyunsaturates on Bone Modelling and Cartilage Function" (1998) in "The Return of  $\omega$ -3 Fatty Acids into the Food Supply I" (Simopoulos, AP ed.), World Rev Nutr Diet, Basel, Karger, vol. 8, pp38-51 discloses chick-feed compositions comprising  $\omega$ -3 fatty acids and its effects on bone composition.

**[0004]** Long bone growth and bone modeling are regulated by complex interactions between a puppy's genetic potential, environmental influences, and nutrition. These interactions produce a bone architecture that balances functionally appropriate morphology with the skeleton's role in calcium and phosphorous homeostasis. Long bones of the dog increase in length and diameter by a process called modeling. Bone modeling represents an adaptive process of generalized and continuous growth and reshaping of bone governed by the activities of osteoblasts and osteoclasts until the adult bone structure is attained. Bone modeling is distinct from bone remodeling which describes the process of bone resorption and formation that maintains skeletal mass in the adult dog.

**[0005]** There are numerous cell-derived growth regulatory factors present within skeletal tissues such as prostaglandins, cytokines, and growth factors which affect skeletal metabolism. Prostaglandins are believed to play a major role in bone metabolism, but also have been implicated in joint diseases. Some of the skeletal abnormalities and conditions in canines are the consequence of abnormal bone remodeling and metabolism, or in the case of arthritis, an inflammatory process.

**[0006]** Growth cartilage in long bones contains chondrocytes which initiate bone mineralization through matrix vesicles which have been described as lipid-enclosed microenvironments containing acidic phospholipids that exhibit a high affinity for binding calcium ions. Polyunsaturated fatty acids (PUFA) are believed to play an important role in bone mineralization and growth because it is believed that phospholipids as well as prostaglandins are synthesized from essential PUFA.

**[0007]** Recent studies have demonstrated that dietary n-6/n-3 fatty acids ratios are reflected in the fatty acid profile in the bones and growth cartilage of growing chicks and in the bones of rats. In these studies, chicks provided with soybean oil in their diet had greater values for ex vivo PGE<sub>2</sub> (prostaglandin E<sub>2</sub>) production in liver and bone cultures, but lower bone formation rates as compared to chicks fed menhaden oil. The level of PGE<sub>2</sub> produced locally at the bone appears to be a critical factor in bone formation in that it is stimulatory at moderate levels and inhibitory at high levels. The mechanism by which prostaglandins regulate bone metabolism is uncertain but it has been suggested that it may be mediated through the IGF system and(or) cytokines.

**[0008]** Accordingly, the need remains in the art for a diet which promotes bone/cartilage biology and health in the growing canine, which diet includes appropriate amounts of dietary n-6 and n-3 fatty acids.

**[0009]** The present invention meets that need by providing means for administering to a growing canine a pet food composition comprising an appropriate amount and ratio of dietary n-6 and n-3 fatty acids to provide improved bone modeling and chondrocyte functioning. Specifically, in one aspect the present invention provides the use of n-6 and n-3 fatty acids in the manufacture of a therapeutic pet food composition for use in improving bone modeling and chondrocyte functioning in a growing canine, wherein the ratio of n-6 to n-3 fatty acids is from 20:1 to 1:1.

**[0010]** In another aspect, the present invention provides a non-therapeutic process for use in improving bone modeling and chondrocyte functioning in a growing canine, the process comprising including n-6 and n-3 fatty acids in the diet of a growing canine, wherein the ratio of n-6 to n-3 fatty acids is from 20:1 to 1:1.

**[0011]** Of relevance to these aspects, and described herein, is a process for improving bone modeling and chondrocyte functioning in a growing canine comprising the step of feeding the growing canine a pet food composition comprising n-6 and n-3 fatty acids in an amount and ratio effective to improve bone modeling and chondrocyte functioning. The ratio of n-6 fatty acids to n-3 fatty acids is preferably from 10:1 to 5:1, and more preferably, from 8:1 to 5:1. It is preferred that at least 22 wt% of the total fatty acids in the pet food composition are n-6 fatty acids. It is also preferred that at least 3 wt% of the total fatty acids in the pet food composition are n-3 fatty acids.

**[0012]** Preferably, the pet food composition comprises from 0.88 to 6.6% by weight n-6 fatty acids and from 0.16 to 1.2% by weight n-3 fatty acids, on a dry matter basis. Thus, both the amount of n-3 fatty acids in the pet food composition, as well as the ratio of n-6 to n-3 fatty acids, are important. In a preferred embodiment, the n-3 fatty acids provided in the pet food composition comprise eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA).

**[0013]** Preferably, the pet food composition comprises from 20 to 40 total dietary fiber, and a source of carbohydrates. No specific ratios or percentages of these nutrients are required.

**[0014]** The pet food composition may further comprise from about 1 to about 11 weight percent of supplemental total dietary fiber of fermentable fibers which have an organic matter disappearance of 15 to 60 weight percent when fermented by fecal bacteria for a 24 hour period.

**[0015]** Accordingly, it is a feature of the present invention to provide a means for improving bone modeling and chondrocyte functioning in a growing canine. This, and other features and advantages of the present invention will become apparent from the following detailed description and the appended claims.

**[0016]** Described herein is a pet food composition which aids in promoting bone development in growing canines by providing appropriate amounts of n-6 and n-3 fatty acids, and in proper ratios, to stimulate chondrocyte functioning and bone development. The pet food composition may be provided in any suitable form as long as it contains the preferred concentrations of n-3 and n-6 fatty acids.

**[0017]** In adult canines, abnormal bone remodeling and metabolism can cause skeletal pathologies. Feeding the pet food composition of the present invention to growing canines early in life may delay or lessen the onset and severity of some of these pathologies. Therefore, growing canines will especially benefit from being fed the pet food composition of the present invention.

**[0018]** It has been discovered that by adjusting the ratio of n-6 to n-3 fatty acids in the pet food composition, the level of certain pro-inflammatory eicosanoid prostaglandins (PGE<sub>2</sub>) are depressed. In accordance with the preferred n-6 fatty acids to n-3 fatty acids that is from 20:1 to 1:1. More preferably, this weight ratio is from 10:1 to 5:1. Most preferably, this weight ratio is from 8:1 to 5:1. Preferably, at least 22 wt% of the total fatty acids in the pet food composition are n-6 fatty acids. It is also preferred that at least 3 wt% of the total fatty acids in the pet food composition are n-3 fatty acids. The pet food composition also preferably comprises from 0.88 to 6.6% by weight n-6 fatty acids and from 0.16 to 1.2% by weight n-3 fatty acids, on a dry matter basis.

**[0019]** Synthesis and tissue accumulation of down regulating elements of inflammation such as the n-3 fatty acids eicosapentaenoic and docosahexaenoic acids (EPA and DHA, respectively) are also promoted by adjusting the ratio of n-6 to n-3 fatty acids in the pet food composition described herein, which stimulates bone formation and optimizes bone modeling. Further, by providing specific sources of n-3 fatty acids to the pet food composition, tissue accumulation of antiinflammatory PGE<sub>3</sub> series prostaglandins is promoted as well. Preferably, the n-3 fatty acids of the pet food composition of the present invention comprise EPA and DHA.

**[0020]** The pet food composition can be any suitable pet food formula that also provides adequate nutrition for the animal. For example, a typical canine diet for use in the present invention may contain from 20 to 40 wt% crude protein, from 4 to 30 wt% fat, and from 2 to 20 wt% total dietary fiber, along with a source of carbohydrates. Suitable sources of protein for use in the pet food composition include, but are not limited to, chicken and chicken-by-products, chicken digest, brewers dried yeast, and DL-methionine. Suitable sources of fat include chicken fat (preserved with mixed tocopherols), fish oil, and flax.

**[0021]** The pet food composition described herein may also optionally contain a source of fermentable fibers that display certain organic matter disappearance percentages. The fermentable fibers that may be used have an organic matter disappearance (OMD) of from 15 to 60 percent when fermented by fecal bacteria in vitro for a 24 hour period. That is, from 15 to 60 percent of the total organic matter originally present is fermented and converted by the fecal bacteria. The organic matter disappearance of the fibers is preferably 20 to 50 percent, and most preferably is 30 to 40 percent.

**[0022]** Thus, in vitro OMD percentage may be calculated as follows:

$$\{1 - [(OM \text{ residue} - OM \text{ blank}) / OM \text{ initial}] \} \times 100,$$

where OM residue is the organic matter recovered after 24 hours of fermentation, OM blank is the organic matter recovered in corresponding blank tubes (i.e., tubes containing medium and diluted feces, but no substrate), and OM initial is that organic matter placed into the tube prior to fermentation. Additional details of the procedure are found in Sunvold et al., J. Anim. Sci. 1995, vol. 73:1099-1109.

**[0023]** The fermentable fibers may be any fiber source that intestinal bacteria present in the animal can ferment to produce significant quantities of short chain fatty acids (SCFAs). "Significant quantities" of SCFAs, for purposes of this invention, are amounts over 0.5 mmol of total SCFAs/gram of substrate in a 24-hour period. Preferred fibers include beet pulp, gum arabic (including gum talha), psyllium, rice bran, carob bean gum, citrus pulp, pectin, fructooligosaccharids and inulin, and mannanoligosaccharides.

**[0024]** The fermentable fibers are used in the pet food composition in amounts from 1 to 11 weight percent of supplemental total dietary fiber, preferably from 2 to 9 weight percent, more preferably from 3 to 7 weight percent, and most preferably from 4 to 7 weight percent.

**EP 1 255 546 B9 (W1B1)**

**[0025]** A definition of "supplemental total dietary fiber" first requires an explanation of "total dietary fiber". "Total dietary fiber" is defined as the residue of plant food which is resistant to hydrolysis by animal digestive enzymes. The main components of total dietary fiber are cellulose, hemicellulose, pectin, lignin, and gums (as opposed to "crude fiber", which only contains some forms of cellulose and lignin). "Supplemental total dietary fiber" is that dietary fiber which is added to a food product above and beyond any dietary fiber naturally present in other components of the food product. Also, a "fiber source" is considered such when it consists predominantly of fiber.

**[0026]** In order that the invention may be more readily understood, reference is made to the following examples, which are intended to be illustrative of the invention, but are not intended to be limiting in scope.

Example 1

**[0027]** A canine study evaluated the dietary n-3 and n-6 fatty acid effects on the fatty acid composition of bone compartments in coonhounds. A total of 32 eight-week-old purpose-bred puppies were allocated to four dietary treatments differing only in fatty acid source. Treatment diets were isonitrogenous, isocaloric and formulated to provide n-6/n-3 ratios ranging from 5:1 to 50:1. The canine growth diet was formulated to contain different ratios of n-6/n-3 fatty acids, 5:1, 5:1, 50:1, and 25:1, using the following lipid sources: docosahexaenoic acid (DHA), menhaden oil (MEN), safflower oil (SAF) and poultry fat (control). Treatments 3 and 4 evaluated the effect of n-3 fatty acid source (Treatment 3 = DHA; Treatment 4 = DHA). Puppies were fed the treatment diets for a total of 18 weeks, 2 of weeks conditioning followed by 16 weeks of treatment. The results of the study are reported below.

Treatment No.	Fat Source	n-6/n-3 Ratio*
1	Poultry Fat	25:1
2	Safflower Oil	50:1
3	Menhaden Oil	5:1
4	DHA Source	5:1

\* Reported ratio is of the Fat Source.

**[0028]** The response criteria evaluated was as follows:

Days on Test	Response Criteria
0	Serum TNF, IL-1 and IL-6.
4	Serum TNF, IL-1 and IL-6.
8	Serum TNF, IL-1, IL-6, lipids, osteocalcin, alkaline phosphatase and IGF-1.
12	Serum TNF, IL-1 and IL-6.
16	Serum TNF, IL-1, IL-6, lipids, osteocalcin, alkaline phosphatase and IGF-1. Bone (Ileum) formation rate, histomorphometry, fatty acids.

**[0029]** MEN and DHA diets elicited significant elevations in 22:6n-3 (DHA) relative to the control diet in neutral and polar lipids of tibia cortical and trabecular bone, marrow and periosteum. The MEN diet resulted in a significantly higher concentration of 20:5n-3 (EPA) in both lipid fractions of all tissues. The concentration of 18:2n-6 (linoleic acid) was significantly higher in both lipid fractions of all tissues except marrow polar lipids of those given the SAF diet. The MEN and DHA diets depressed 18:2n-6 in the polar lipid fractions of trabecular bone and marrow. In the MEN and DHA enriched diets, arachidonic acid (AA; 20:4n-6) concentration was significantly depressed and 22:6n-3 elevated in the neutral lipid fraction of periosteum. Both the MEN and DHA diets reduced 18:2n-6 and increased n-3 fatty acids in ligaments compared to the values in dogs given control and SAF-containing diets.

**[0030]** These data showed that both EPA and DHA were enriched in bone compartments, and that DHA accumulated to a greater extent in cortical bone polar lipids than EPA. Based on ex vivo PGE<sub>2</sub> production in iliac crest tissue, the MEN diet tended to lower prostanoid formation. Moreover, the down-regulating elements of inflammation (PGE<sub>3</sub>) are stimulated by the presence of EPA. These results suggest that diets rich in n-3 fatty acids reduce pro-inflammatory eicosanoid (PGE<sub>2</sub>) synthesis and promote tissue accumulation of down-regulating elements of inflammation (EPA and DHA) in bone compartments of canines. These results also suggest that pro-inflammatory PGE<sub>2</sub> production will be elevated by a dietary n-6/n-3 fatty acid ratio of 25:1 or greater and thereby depress bone formation, while a ratio of 5:1 will lower the level of PGE<sub>2</sub> and thereby stimulate bone formation and optimize bone modeling in the growing canine. The specific n-3 fatty acid (20:5n-3 or 22:6n-3) in the diet may also differentially modulate effects on cartilage and bone metabolism in the growing canine.

Example 2

**[0031]** A study using rats was performed. The study was needed due to the nature of the data to be collected and the impracticality of collecting such data from the growing canine. Data collected included (1) harvesting of organs and tissues, (2) determination of bone formation rates (BFR) and growth cartilage morphometry as a measure of bone modeling, and (3) evaluation of mechanical properties on intact bones.

**[0032]** A total of 40 weanling male Harlan Sprague-Dawley rats (21 days old) were allocated to four dietary treatments for 42 days. The control diet (Treatment 1) was AIN93G (diet as reported by Reeves et al, *AIN-93 Purified Diets for Laboratory Rodents*, 123 J. Nutrition 1939-51 (1993)) that contained soybean oil and an n-6/n-3 fatty acid ratio of 8:1. The other three treatment diets provided supplemental fatty acids to mirror the n-6/n-3 fatty acid ratios of the canine experiment as closely as possible. The control diet contained 70 g/kg of added fat. The other three treatment diets were formulated with lipids to provide the following ratios of (n-6)/(n-3) fatty acids: 8:1 (soybean oil (SBO)), 50:1 (safflower oil (SAF)), 5:1 (docosahexaenoic acid (DHA)), and 5:1 (Menhaden oil (MEN)). Treatment diets are summarized in the following table:

Treatment No.	Fat Source	n-6/n-3 Ratio*
1	Soybean oil	8:1
2	Safflower Oil	50:1
3	Menhaden Oil	5:1
4	DHA Source	5:1

\* Reported ratio is of the Fat Source.

**[0033]** The response criteria evaluated was as follows:

Days on Test	Response Criteria
21	Serum IGF-1, BP-3, osteocalcin and alkaline phosphatase.
42	Serum IGF-1, BP-3, osteocalcin, alkaline phosphatase and fatty acids. Bone histomorphometric measurements on growth plate cartilage and trabecular bone. Bone fatty acids, PGE <sub>2</sub> and IGF-1. Tibia and femur mechanical properties.

**[0034]** The MEN and DHA diets significantly elevated the concentrations of 20:5n-3 (EPA) and 22:6n-3 (DHA) in tibia cortical bone and marrow compared to the values in those given the SAF diet. The concentration of 20:4n-6 (AA) in bone compartments was unchanged by the dietary treatments. The DHA concentration in bone was lowest in rats given the SAF diet.

**[0035]** These data showed that both EPA and DHA were enriched in bone compartments, and that DHA accumulated to a greater extent in cortical bone polar lipids than EPA. *Ex vivo* PGE<sub>2</sub> production in the tibia was reduced in rats given the DHA diet compared to those on the SAF diet. Serum bone specific alkaline phosphatase was elevated in rats given the MEN diet compared to values in rats given the other diets. Total trabecular number and marrow area were higher in the DHA group compared with the SBO group; however, periosteal BFR was higher in those given the SBO and SAF diets. No differences were found between the dietary treatments for endosteal bone formation rates.

**[0036]** The results suggest that diets rich in n-3 fatty acids reduce pro-inflammatory eicosanoid (PGE<sub>2</sub>) synthesis and promote tissue accumulation of down-regulating elements of inflammation (EPA and DHA) in bone compartments.

**Claims**

1. The use of a composition comprising n-6 and n-3 fatty acids in the manufacture of a therapeutic diet for use in improving bone modelling and chondrocyte functioning in a growing canine wherein the ratio of n-6 fatty acids to n-3 fatty acids in the diet is from 20:1 to 1:1.
2. The non-therapeutic use of a diet comprising n-6 and n-3 fatty acids, the ratio of n-6 to n-3 fatty acids in the diet being from 20:1 to 1:1, in improving bone modelling and chondrocyte functioning in a growing canine.
3. The use as claimed in claim 1 or claim 2 in which the ratio of n-6 fatty acids to n-3 fatty acids in the diet is from

## EP 1 255 546 B9 (W1B1)

10:1 to 5:1.

4. The use as claimed in any one of the preceding claims in which the ratio of n-6 fatty acids to n-3 fatty acids in the diet is from 8:1 to 5:1.

5. The use as claimed in any one of the preceding claims in which at least 22 wt% of the total fatty acids in the diet are n-6 fatty acids.

6. The use as claimed in any one of the preceding claims in which at least 3 wt% of the total fatty acids in the diet are n-3 fatty acids.

7. The use as claimed in any one of the preceding claims in which the diet comprises from 0.88 to 6.6% by weight n-6 fatty acids and from 0.16 to 1.2% by weight n-3 fatty acids, on a dry matter basis.

8. The use as claimed in any one of the preceding claims in which the n-3 fatty acids of the diet comprise eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA).

9. The use as claimed in any one of the preceding claims wherein the diet is manufactured to include from 20 to 40 wt% crude protein, from 4 to 30 wt% fat, from 2 to 20 wt% total dietary fiber, and a source of carbohydrate.

10. The use as claimed in claim 9 wherein the diet further includes from 1 to 11 wt% of supplemental total dietary fiber of fermentable fibers which have an organic matter disappearance of 15 to 60 wt% when fermented by fecal bacteria for a 24 hour period.

### Patentansprüche

1. Verwendung einer Zusammensetzung, die n-6- und n-3-Fettsäuren umfasst, bei der Herstellung einer therapeutischen Nahrung für den Zweck der Verbesserung von Knochenaufbau und Chondrozytenfunktion in einem heranwachsenden Caniden, bei der das Verhältnis von n-6- zu n-3-Fettsäuren in der Nahrung 20:1 bis 1:1 ist.

2. Nicht-therapeutische Verwendung einer Nahrung, die n-6- und n-3-Fettsäuren umfasst, bei der das Verhältnis von n-6- zu n-3-Fettsäuren in der Nahrung 20:1 bis 1:1 ist, zur Verbesserung des Knochenaufbaus und der Chondrozytenfunktion in einem heranwachsenden Caniden.

3. Verwendung nach Anspruch 1 oder Anspruch 2, wobei das Verhältnis von n-6-Fettsäuren zu n-3-Fettsäuren in der Nahrung 10:1 bis 5:1 ist.

4. Verwendung nach einem beliebigen der vorstehenden Ansprüche, wobei das Verhältnis von n-6-Fettsäuren zu n-3-Fettsäuren in der Nahrung 8:1 bis 5:1 ist.

5. Verwendung nach einem beliebigen der vorstehenden Ansprüche, wobei mindestens 22 Gew.-% der gesamten Fettsäuren in der Nahrung n-6-Fettsäuren sind.

6. Verwendung nach einem beliebigen der vorstehenden Ansprüche, wobei mindestens 3 Gew.-% der gesamten Fettsäuren in der Nahrung n-3-Fettsäuren sind.

7. Verwendung nach einem beliebigen der vorstehenden Ansprüche, wobei die Nahrung von 0,88 bis 6,6 Gew.-% n-6-Fettsäuren und von 0,16 bis 1,2 Gew.-% n-3-Fettsäuren auf Trockensubstanzbasis umfasst.

8. Verwendung nach einem beliebigen der vorstehenden Ansprüche, wobei die n-3 Fettsäuren der Nahrung Eicosapentaensäure (EPA) und Docosahexansäure (DHA) umfassen.

9. Verwendung nach einem beliebigen der vorstehenden Ansprüche, wobei die Nahrung so hergestellt wird, dass sie 20 bis 40 Gew.-% Rohprotein, 4 bis 30 Gew.-% Fett, 2 bis 20 Gew.-% Gesamtballaststoffe und eine Quelle für Kohlenhydrate enthält.

10. Verwendung nach Anspruch 9, wobei die Nahrung des Weiteren 1 bis 11 Gew.-% ergänzende Gesamtballaststoffe

## EP 1 255 546 B9 (W1B1)

als gärfähige Fasern enthält, die einen Schwund organischer Materie von 15 bis 60 Gew.-% haben, wenn sie für eine Dauer von 24 Stunden von Fäkalbakterien vergoren werden.

### 5 **Revendications**

1. Utilisation d'une composition comprenant des acides gras n-6 et n-3 dans la fabrication d'un régime alimentaire thérapeutique approprié à être utilisé pour améliorer le modelage osseux et l'activité des chondrocytes chez un canin en cours de croissance, dans laquelle le rapport des acides gras n-6 sur n-3 dans le régime alimentaire va de 20/1 à 1/1.  
10
2. Utilisation d'un régime alimentaire non thérapeutique comprenant des acides gras n-6 sur n-3, le rapport des acides gras n-6 et n-3 allant de 20/1 à 1/1, pour améliorer le modelage osseux et l'activité des chondrocytes chez un canin en cours de croissance.  
15
3. Utilisation selon la revendication 1 ou la revendication 2 dans laquelle le rapport d'acides gras n-6 sur les acides gras n-3 dans le régime alimentaire est de 10/1 à 5/1.
4. Utilisation selon l'une quelconque des revendications précédentes dans laquelle le rapport d'acides gras n-6 sur les acides gras n-3 dans le régime alimentaire est de 8/1 à 5/1.  
20
5. Utilisation selon l'une quelconque des revendications précédentes dans laquelle au moins 22 % en poids des acides gras totaux dans le régime alimentaire sont des acides gras n-6.
- 25 6. Utilisation selon l'une quelconque des revendications précédentes dans laquelle au moins 3 % en poids des acides gras totaux dans le régime alimentaire sont des acides gras n-3.
7. Utilisation selon l'une quelconque des revendications précédentes dans laquelle le régime alimentaire comprend de 0,88 à 6,6 % en poids d'acides gras n-6 et de 0,16 à 1,2 % en poids d'acides gras n-3, sur la base de la matière sèche.  
30
8. Utilisation selon l'une quelconque des revendications précédentes dans laquelle les acides gras n-3 du régime alimentaire comprennent l'acide eicosapentaénoïque (EPA) et l'acide docosahexaénoïque (DHA).
- 35 9. Utilisation selon l'une quelconque des revendications précédentes dans laquelle le régime alimentaire est fabriqué pour inclure de 20 à 40 % en poids de protéines brutes, de 4 à 30 % en poids de lipides, et de 2 à 20 % en poids de fibre alimentaire totale, ainsi qu'une source de glucides.
- 40 10. Utilisation selon la revendication 9, dans laquelle le régime alimentaire comprend en outre de 1 à 11 % en poids de fibre alimentaire totale supplémentaire de fibres fermentescibles qui ont une dégradation de matière organique de 15 à 60 % en poids lorsqu'elles sont fermentées par des bactéries fécales pendant une période de 24 heures.

45

50

55